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medical costs that might accrue to soci-
ety through implementation of the ferric 
gluconate treatment strategy. After this 
analysis was completed, secondary analyses 
could perform evaluations from the payer 
and provider perspectives. The use of alter-
native perspectives is important because, 
while the use of a new therapy versus 
standard of care may be good for society, 
its implementation frequently depends 
on its making economic sense from key 
secondary perspectives. In this instance, it 
appears that payers will gain through lower 
reimbursements for anemia therapies and 
patient hospitalizations, while dialysis 
facilities will lose revenues from reduced 
epoetin alfa use. Thus, economic incen-
tives may be required to encourage dialysis 
facilities to adopt the ferric gluconate treat-
ment strategy.
In 2003, the Centers for Medicare & 
Medicaid Services (CMS) created two 
new Diagnosis Related Groups to cover 
the expected costs associated with drug-
eluting stents. While these groups were cre-
ated before Food and Drug Administration 
approval of the first drug-eluting stent, they 
were based on clinical trial results demon-
strating reductions in repeat revasculari-
zation procedures. In this situation, CMS 
was creating a financial mechanism that 
would allow hospitals to use a viable new 
technology without being financially disad-
vantaged. Perhaps a similar incentive could 
be used in the present situation.
Clearly, the results of Pizzi and col-
leagues7 point to the potential economic 
attractiveness of a ferric gluconate treat-
ment strategy. While these results serve to 
frame Cochrane’s efficiency question and 
are credible, they may not be sufficient 
of themselves to change public policy 
and reimbursement practices. What is 
required is a large, simple trial that will 
replicate the DRIVE results in a broader 
population with longer follow-up and a 
prospectively defined economic and qual-
ity-of-life study conducted from the soci-
etal perspective. Such a trial would both 
address the public policy and reimburse-
ment questions and serve as a model for 
how to incorporate prospective economic 
data collection into randomized clinical 
trials of kidney disease patients.
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First responders: understanding 
monocyte-lineage traffic in the 
acutely injured kidney
Sundararaman Swaminathan1 and Matthew D. Griffin2
Interstitial monocytic infiltration of the kidney occurs within hours of 
acute kidney injury and is an important determinant of functional decline 
and fibrosis. Li et al. used several surface markers to distinguish between 
dendritic cells and inflammatory monocytes following acute kidney injury 
and to identify two chemokine receptors that regulate monocyte traffic. This 
Commentary examines the degree to which monocyte-lineage diversity, 
trafficking, and contribution to renal injury have been teased out to date.
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Bone marrow-derived cells play a central 
part in the acute response of the kidney 
to ischemia–reperfusion (IR) and other 
forms of injury. In the hours and days 
following IR, conventional histology 
readily indicates the increased presence 
of polymorphonuclear leukocytes, lym-
phocytes, and monocytes in the renal 
interstitial spaces. Furthermore, a variety 
of experimental approaches confirm that 
such infiltrating cells participate both 
in the harmful processes (widespread 
apoptosis, increased interstitial fibro-
sis, loss of peritubular capillaries) that 
compromise renal function and in the 
healing phase of injury.1 Thus, strategies 
to manipulate the traffic and function of 
bone marrow-derived cells represent a 
promising direction for translational 
research in acute kidney injury (AKI). 
Surprisingly, however, while progress 
in the field of immunology has revealed 
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remarkable developmental, phenotypic, 
and functional diversity within each of 
the basic leukocyte subtypes, there has 
been relatively little attention given to 
accurately characterizing renal inter-
stitial bone marrow-derived cells dur-
ing health and at different time points 
following AKI. As an example of this, it 
has been common to refer to interstitial 
cells stained with a single cell-surface 
marker (for example, F4/80 or CD68) as 
‘monocyte/macrophages,’ even though 
the designation has little immuno logical 
precision.
Li et al.2 (this issue) report results of a 
comprehensive study that illustrates the 
wealth of information that remains to be 
gathered regarding the roles played by 
monocyte subtypes and by monocyte-
derived lineages (macrophages and 
dendritic cells) at each stage of AKI. 
Key strengths of this and recent simi-
lar studies are the application of multi-
color flow cytometry to define cell types 
on the basis of several cell-surface and 
intracellular proteins, the construction 
of a ‘timeline’ for cellular events, and 
the correlation of data derived from the 
kidney with a broader immunological 
literature.2–4 Most convincingly, Li et 
al.2 use a ‘multiple marker’ approach to 
demonstrate the rapid accumulation fol-
lowing IR of a distinct cell population 
expressing F4/80 and CX3CR1 at low 
levels, along with CD11b and Ly6C at 
high levels. Furthermore, they distin-
guish this cell type (which is infrequent 
in the healthy kidney) from a popula-
tion that expresses high levels of F4/80 
and CX3CR1, low levels of CD11b, and 
no Ly6C, and is already abundant in the 
kidney before injury.2 By correlation 
with existing reports and staining for a 
panel of additional markers, these two 
cell populations could be accurately cat-
egorized as ‘inflamed monocytes’ — cells 
that can be rapidly recruited from their 
pool in the peripheral blood, contribute 
a variety of proinflammatory mediators 
to the interstitial microenvironment, 
and additionally have the potential to 
terminally differentiate into both tissue 
macrophages and dendritic cells (DCs);5 
and ‘resident DCs’ — cells that act as 
sentinels for immediate response to tis-
sue injury and, following maturation, 
have the capacity for potent antigen 
presentation to T cells both locally and 
following migration to draining lymph 
nodes.3,4 Thus, the oversimplification 
associated with a single marker designa-
tion (‘F4/80+ macrophages’) is exposed 
by a more sophisticated approach.
It is interesting to note that recent 
studies involving flow cytometry and 
multicolor immunofluorescence micro-
scopy to better reveal the true nature of 
bone marrow-derived cells in the renal 
interstitium were presaged somewhat 
by elegant ultrastructural investigations 
that, in similar fashion, utilized multiple 
subcellular characteristics and correla-
tion with the immunological literature 
to more accurately define these cells. 
On the basis of this work, it was, in fact, 
known, but seldom clearly acknowl-
edged, that DCs are the predominant 
leukocyte in the normal peritubular 
interstitium whereas true macrophages 
are less numerous and are sequestered 
in the periarterial spaces.6 Such stud-
ies also emphasize the important point 
that even shared expression of multiple 
markers may not be sufficient to fully 
eliminate heterogeneity within a cell 
population. In the absence of ultrastruc-
tural and functional characterization, 
therefore, one question of interest 
remaining from the study of Li et al.2 is 
the degree to which the inflamed mono-
cytes infiltrating the kidney following IR 
remain phenotypically and functionally 
plastic as opposed to differentiating fully 
into true macrophages, DCs, or both. Of 
additional great interest will be studies 
that can further subcategorize mono-
cytes, macrophages, and DCs during 
a postinjury timeline according to the 
diverse functional programs that appear 
to be imprinted on them as a result of 
signals received via cross-talk with 
each other and with cells of the injured 
parenchyma.1
To condense the insights gleaned by 
Li et al.2 and other groups regarding the 
participation of monocytes and mono-
cyte-derived lineages in the renal acute 
injury response, we propose, in Figure 1, 
a schematic, not unlike the response to 
a highway accident, in which these cell 
lineages play key roles at all time points, 
acting as sentinels, alarm raisers, first 
responders, specialized responders, and 
clean-up crew. To extend the analogy a 
Figure 1 | A model for the participation of monocytes and monocyte-derived lineages 
(macrophages and dendritic cells) in the dynamic response to acute ischemia–reperfusion 
injury to the kidney. Abbreviations: DC, dendritic cell; IL, interleukin; IRI, ischemia–reperfusion 
injury; Mφ, macrophage; NO, nitric oxide; ROS, reactive oxygen species; TNF, tumor necrosis factor.
Functions
Monocytes
Macrophages
Dendritic cells
Precursors
for DC and
Mφ turnover. 
Infrequent.
Quiescent in
periarterial
interstitium.
Numerous.
Quiescent in
periarterial
interstitium.
Inflammatory monocytes 
mobilized into bloodstream 
from bone marrow.
Large influx into interstitium. 
Secrete pro-inflammatory 
cytokines and chemokines.
Differentiate into new DC and Mφ 
populations. May continue to 
secrete cytokines and chemokines. 
Precursors for new steady-state 
dc and Mφs.
IRI
Response not
defined; may secrete 
proinflammatory factors.
Maturation response.
TNF production. Secrete 
multiple other cytokines 
and chemokines.
Begin to differentiate from 
inflamed monocytes.
Remain in situ.
Ongoing cytokine and 
chemokine secretion.  
Antigen uptake. 
Migration to draining lymph 
nodes; antigen presentation.
New DC populations from 
monocytes—unknown role.
M1 phenotype: production
of NO, ROS, IL-12. Phagocytosis 
of apoptotic cells. Profibrogenic.
M2 phenotype: production of 
IL-10, other anti-inflammatory 
cytokines. Antifibrogenic.
Production of anti-inflammatory 
cytokines. Return to quiescent 
state. May maintain tolerance to 
self-antigens.
Re
n
al
 
in
te
rs
tit
iu
m
Role
(time)
Sentinels
(healthy kidney)
Alarm
raisers
(0–3 h)
First
responders
(3–24 h)
Specialized
responders
(48–72 h)
Clean-up
crew
(72+ h)
Kidney International (2008) 74          1511
commentar y
little further, it is worth considering that 
each role requires not just a separate set 
of skills but a series of communication 
events that provide the optimal transi-
tion from immediate first aid and stabili-
zation to sophisticated multidisciplinary 
care. It is in this area of communication 
signals for monocyte trafficking follow-
ing renal IR that Li et al.2 also provide 
important new data. Renal IR is associ-
ated with upregulation of a multitude 
of proinflammatory cytokines and che-
moattractants (chemokines) that are 
involved both in propagation of tissue 
injury and in healing through their 
diverse effects on each of the resident 
and recruited cell types. Most proin-
flammatory chemokines are not con-
stitutively expressed in the kidney and 
require transcriptional activation by 
complement factors, cytokines (tumor 
necrosis factor, interleukin-1β (IL-1β), 
IL-8, and interferon-γ), reactive oxygen 
species, toll-like receptors, NF-κB, and 
AP-1. Chemokines have been classified 
into families based on the number and 
spacing of key cysteine residues (C, CC, 
CXC, and CX3C) and may have precise 
or loose specificity for individual recep-
tors and for one or more leukocyte line-
ages. Examples of chemokines that hold 
particular relevance to AKI include 
CXCL8/IL-8 (CXC family), which acts 
primarily on neutrophils; CCL2/mono-
cyte chemoattractant protein-1 (MCP-1) 
(CC family) and CX3CL1/fractalkine 
(CX3C family), which have specific 
effects on monocytes and monocyte-
derived lineages; CXCL10, which is 
targeted toward activated T cells with 
a T-helper 1 differentiation phenotype; 
and CCL5/RANTES, which operates 
more broadly to attract cells of mono-
cytic and lymphocytic origin.
Conceptually, interventions aimed 
at blocking or augmenting individual 
chemokines or their receptors dur-
ing the course of an acute renal injury 
could provide a potent means for redi-
recting the traffic of potentially harm-
ful cells such as inflamed monocytes or 
for influencing the functional profile of 
their progeny (macrophages and DCs). 
However, determining the role of sin-
gle chemokine species in the context 
of in vivo models is complicated by 
several factors, including chemokine/
chemokine receptor redundancy, syner-
gistic effects of different chemokines on 
cell populations of interest, promiscuity 
of chemo kine pathways across leukocyte 
lineages, and broad diversity among the 
cellular sources for chemokines. Thus, 
identifying the chemokines that are 
specifically responsible for early recruit-
ment of bone marrow-derived lineages 
following renal IR along with their cel-
lular sources and target receptors as well 
as determining the consequences of 
blocking them represents a substantial 
experimental challenge. Several pivotal 
studies have addressed the importance 
of chemo kine axes in inflammation 
and renal tubular injury associated 
with IR. For example, administration 
of an inhibitor of CXCR2 (CXCL8/IL-8 
axis in humans) resulted in reduction 
of neutrophil infiltration and of acute 
tubular necrosis in a rat IR model.7 
More recently, Fiorina et al. showed 
that abrogation of CXCR3 signaling in 
a mouse model of renal IR resulted in 
decreased infiltration of interferon-γ-
producing CD4+ T cells and decreased 
the severity of acute tubular necrosis.8 In 
the study of Li et al.,2 mouse knockouts 
for CCR2, CCL2 (MCP-1, one of several 
CCR2 ligands), and CX3CR1 have been 
elegantly combined with the techniques 
of bone marrow transfer, multicolor flow 
cytometry, and adoptive cell transfer 
to make quite precise observations on 
the homing signals for inflamed mono-
cytes following acute IR. Through these 
experiments it is nicely demonstrated 
that CCR2 expression is necessary both 
for acute release of inflamed monocytes 
from the bone marrow and for infiltra-
tion of these cells into the injured kid-
ney. Other interesting observations were 
very much in keeping with the complex-
ity of chemokine biology. For example, 
CCR2 ablation also reduced neutrophil 
infiltration (promiscuity); absence of 
the most widely studied CCR2 ligand, 
CCL2/MCP-1, did not reduce renal 
monocyte infiltration or its harmful 
effects (ligand redundancy); and abla-
tion of CX3CR1 expression by mono-
cytes also greatly diminished monocyte 
trafficking to the kidney (overlap and, 
possibly, synergy).
When added to the results of prior 
studies in this area,9,10 the findings 
create a strong rationale for target-
ing early monocyte trafficking via 
CCR2 and CXC3R1 in acute renal IR 
both as a means to limit the severity 
of early tubular necrosis and, perhaps, 
as a strategy for reducing IR-related 
injury at distal sites such as the heart 
and lungs. Some word of caution is also 
merited, however, given the evidence 
that monocyte-derived cells, including 
both macrophages and DCs, may also 
participate at later time points in halt-
ing inflammation and limiting chronic 
parenchymal injury.1 Collectively, 
studies such as that by Li et al.2 begin 
to reveal precise and valuable details 
regarding the extensive cross-talk, 
coordination, and convergence that 
occur among the cellular responders 
and their chemokine signals at differ-
ent time points following an episode of 
sudden renal injury.
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